Penn Pharmaceuticals December 09 www. bus- ex. com 131 much more work with larger pharmaceutical companies who are seeing a need to work with highly specialised and often more focused companies, such as Penn." Another trend is that the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products ( EMEA) are becoming more discerning about the necessity for pharmaceutical licence applications to pay attention to paediatric needs. " It's difficult to present paediatrics ( and the same is true for geriatrics) with what we may consider conventional dosage forms, such as capsules and tablets," explains Hassey. " That's where the more specialised dosage forms such as fast melts or dispersible drugs that are flavoured, have alcohol removed, etc, are often quite beneficial for those populations. Our ability and skill in delivering and formulating poorly soluble molecules Penn's customers can require any number or combination of services. Virtual pharmaceuticals companies, for example, who merely hold the intellectual property on a single molecule or active ingredient, are likely to require the entire portfolio of services to bring that drug to market. At the other end of the spectrum, the large pharmaceutical giants may require just one of Penn's highly specialised testing or formulating services, or may commission the manufacture of a special drugs trial kit. " From my perspective, Penn is remaining a key service provider to a lot of the small and virtual pharmaceutical companies where we have roots and where we offer a continued strong service, especially in the areas where they only hold intellectual property and are truly virtual," explains Hassey. " But as we grow and continue to develop, we are seeing and driving " Penn is remaining a key service provider to a lot of the small and virtual pharmaceutical companies where we have roots and where we offer a continued strong service"